RxDoctor Payments Data

Brian Keeffe, MD

Cardiovascular Disease · Larkspur, CANPI 1689664492

Payments from drug & device makers

$8,567in general payments, 2019–2025

Across 37 payments — averaging $231.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$4K
  • Heartflow, Inc.$3K
  • Roche Molecular Systems, Inc.$2K
  • Abbott$256
  • Boston Scientific$196
  • Edwards Lifesciences$114
  • plus $37 from 2 others

What the payments were for

  • Consulting fees$4,96758%
  • Travel & lodging$1,99423%
  • Food & beverage$1,59219%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,567 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$445,243
Medicare patients
1,836
Services billed
5,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban751$920,702
Repatha SureclickEvolocumab318$388,276
XareltoRivaroxaban139$197,618
JardianceEmpagliflozin159$172,140
EntrestoSacubitril/Valsartan93$138,171
Praluent PenAlirocumab84$84,814
MultaqDronedarone Hcl34$44,959
OzempicSemaglutide18$16,511
Ezetimibe490$14,842
Metoprolol Succinate752$13,874
Rosuvastatin Calcium673$13,488
Dabigatran EtexilateDabigatran Etexilate Mesylate33$13,373
Atorvastatin Calcium942$11,297
LivaloPitavastatin Calcium13$8,239
BrilintaTicagrelor13$8,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$14$8,13213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Larkspur

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →